Zydus Lifesciences

ZYDUSLIFE · NSE

Public Market Listing

ZYDUSLIFENSE

NSE primary exchange listing

Live quotes, historical charts, and market capitalization for Zydus Lifesciences are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(5 total)
5Total Assets
1Approved
3Phase 3 / Filed
1Phase 1–2 / Early
9Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Approved
VEGF-AMonoclonal antibody
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
Phase 3
CTLA-4Monoclonal antibody
Non-Small Cell Lung CancerColorectal Cancer
Desidustat(Oxemia)
Phase 3
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease
Saroglitazar(Lipaglyn)
Phase 3
PPAR-alpha/PPAR-gammaSmall molecule
Type 2 DiabetesCardiovascular Disease / DyslipidemiaCholestatic Liver Disease
Hypertriglyceridemia, Primary Biliary Cholangitis
Phase 2
PD-1Monoclonal antibody
Non-Small Cell Lung CancerCervical Cancer

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
Saroglitazar · LipaglynPhase 3Primary Biliary Cholangitis
Est. primary completion 2027-04-18 · NCT06427395 · CT.gov ↗
What to watch
September 2027 (1)
Balstilimab + BotensilimabPhase 2Metastatic Colorectal Cancer
Est. primary completion 2027-09 · NCT05608044 · CT.gov ↗
What to watch
2028 (1)
July 2028 (1)
Saroglitazar · LipaglynPhase 3Primary Biliary Cholangitis
Est. primary completion 2028-07 · NCT07424677 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Saroglitazar · LipaglynPhase 3Primary Biliary Cholangitis
Est. primary completion 2032-11 · NCT07216235 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

27 November 2026FDA action dateSaroglitazarPDUFA target action date for saroglitazar in PBC
US, FDA · Zydus Therapeutics (wholly owned subsidiary of Zydus Lifesciences Ltd.) · Source ↗

Recent

October 2026ApprovalBotensilimabArmenia grants the first marketing authorizations for botensilimab and balstilimab
AM, Ministry of Health of Armenia · Agenus Inc. · Source ↗
October 2026ApprovalBalstilimabArmenia grants the first marketing authorizations for botensilimab and balstilimab
AM, Ministry of Health of Armenia · Agenus Inc. · Source ↗
28 May 2026Priority reviewSaroglitazarFDA accepts the saroglitazar NDA in PBC with Priority Review
US, FDA · Zydus Therapeutics (wholly owned subsidiary of Zydus Lifesciences Ltd.) · Source ↗
29 August 2025Topline resultSaroglitazarEPICS-III (NCT05133336) Phase 2(b)/3 met its primary endpoint
Zydus Therapeutics (wholly owned subsidiary of Zydus Lifesciences Ltd.) · Source ↗

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q4$829M$76M——report ↗

Zydus Lifesciences reported revenue of $829.02M, down 69.8% YoY and R&D spend of $76.29M, down 65.2% YoY for Q4 2026.

Figures only: this period's report disclosed no narrative text

View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$771M———report ↗
2026-Q2$702M———report ↗
2026-Q1$769M———report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$3.1B$256M——report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$2.7B$219M——report ↗
2024-FY$2.4B$158M——report ↗
2023-FY$2.1B———report ↗
2022-FY$2.0B$140M——report ↗